NK3 receptor antagonists for the treatment of schizophrenia

Herbert Meltzer*, Adam Prus

*Corresponding author for this work

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).

Original languageEnglish (US)
Pages (from-to)555-560
Number of pages6
JournalDrug Discovery Today: Therapeutic Strategies
Volume3
Issue number4
DOIs
StatePublished - Jun 1 2006

Fingerprint

Schizophrenia
Limbic System
Aptitude
Cholinergic Agents
Antipsychotic Agents
Hippocampus
Therapeutics
Pharmaceutical Preparations
SR 142801
SB 223412

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

@article{df185f4224194db290a7977d3d51591b,
title = "NK3 receptor antagonists for the treatment of schizophrenia",
abstract = "The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).",
author = "Herbert Meltzer and Adam Prus",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.ddstr.2006.11.013",
language = "English (US)",
volume = "3",
pages = "555--560",
journal = "Drug Discovery Today: Therapeutic Strategies",
issn = "1740-6773",
publisher = "Elsevier Limited",
number = "4",

}

NK3 receptor antagonists for the treatment of schizophrenia. / Meltzer, Herbert; Prus, Adam.

In: Drug Discovery Today: Therapeutic Strategies, Vol. 3, No. 4, 01.06.2006, p. 555-560.

Research output: Contribution to journalReview article

TY - JOUR

T1 - NK3 receptor antagonists for the treatment of schizophrenia

AU - Meltzer, Herbert

AU - Prus, Adam

PY - 2006/6/1

Y1 - 2006/6/1

N2 - The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).

AB - The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).

UR - http://www.scopus.com/inward/record.url?scp=33846177867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846177867&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2006.11.013

DO - 10.1016/j.ddstr.2006.11.013

M3 - Review article

AN - SCOPUS:33846177867

VL - 3

SP - 555

EP - 560

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

SN - 1740-6773

IS - 4

ER -